LakeShore Biopharma Calls Extraordinary General Meeting to Vote on Merger Agreement

LakeShore Biopharma Co., Ltd, a global biopharmaceutical company specializing in vaccines and therapeutic biologics, has called an extraordinary general meeting (EGM) of shareholders to vote on a proposed merger that would transition the company from public to private ownership. The EGM is scheduled for June 19, 2026, at 1:00 p.m. Beijing time at the company's headquarters in Beijing, China.

Under the terms of the Agreement and Plan of Merger, dated November 4, 2025, and amended on April 29, 2026, Oceanpine Skyline Inc. (Parent) and its wholly owned subsidiary, Oceanpine Merger Sub Inc., will merge with LakeShore Biopharma. Upon completion, the company will become a wholly owned subsidiary of Parent, and its ordinary shares and warrants will cease to be listed on public markets, including the OTC Pink tier of the OTC Markets. This move will also result in the deregistration of the company's securities under the Securities Exchange Act of 1934.

The decision to pursue the merger was authorized by LakeShore Biopharma's board of directors, following the unanimous recommendation of a special committee of independent directors. The board recommends that shareholders vote in favor of the proposal. Shareholders of record as of May 27, 2026, are entitled to vote at the EGM.

Additional information about the merger and the EGM is available in the transaction statement on Schedule 13E-3 and the definitive proxy statement filed with the U.S. Securities and Exchange Commission (SEC). These documents can be accessed for free on the SEC's website at http://www.sec.gov. The company urges shareholders to read these materials carefully.

The merger represents a significant strategic shift for LakeShore Biopharma, which has developed a proprietary PIKA immunomodulating technology platform and a portfolio of vaccines targeting rabies, hepatitis B, influenza, and other infectious diseases. The company operates in China, Singapore, and the Philippines, and its management team combines local expertise with global industry experience.

Forward-looking statements in the press release highlight uncertainties, including shareholder voting outcomes, potential termination of the merger agreement, and the possibility of competing offers. The company has not provided a timeline for when the merger might close if approved. For investor inquiries, the company can be reached at +86 (10) 8920-2086 or by email at [email protected].